Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610824 | 0.73 | BAZ2B (0.39) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL2737328 | 0.73 | ALDH1A1 (0.35) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL8764618 | 0.71 | MAPK8 (0.32) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL4423855 | 0.71 | NOS3 (0.39) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL8763937 | 0.71 | ALDH1A1 (0.34) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL19209832 | 0.71 | ALDH1A1 (0.32) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL10129937 | 0.68 | LRRK2 (0.35) | GAA | |
| SCHEMBL24956324 | 0.68 | ALDH1A1 (0.33) | ALDH1A1GAA | |
| SCHEMBL9203781 | 0.68 | PDE4B (0.37) | — | |
| SCHEMBL12966919 | 0.68 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ALDH1A1 4437/4885GAA 2164/4885NOS3 4516/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 4437/4885GAA 2164/4885NOS3 4516/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 4437/4885GAA 2164/4885NOS3 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.